In another ongoing phase II clinical trial (NCT03140670), rucaparib is being tested on pancreatic cancer patients with a locally advanced or metastatic disease possessing a germline or somatic deletion in BRCA1/2 or PALB2 mutations [209]. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.